Outcome of Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Patients with Urinary Retention and Small Prostate Volume Based on Urodynamic Finding
DOI:
https://doi.org/10.61841/2ydndp18Keywords:
Benign Prostatic Hyperplasia (BPH), outcome, small prostate volume, trans urethral resection of prostate (TURP), urodynamicsAbstract
The gold standard of treatment in BPH patients with urinary retention is Transurethral resection of the prostate (TURP). This study evaluated the outcome of TURP in BPH patients and urinary retention with small prostate volumes (20-40cc). The 56 patients aged more than 50 years and clinically diagnosed with BPH and urinary retention with prostate volume 20 cc-40 cc were enrolled in this study. We compared all parameters (age, prostate volume, pre-operative urodynamic study, length of urinary retention prior to TURP, post-operative Qmax and PVR) according to the IPSS following TURP. Three-months following TURP, 28 (50%) patients have mild LUTS and 28 (50%) patients have moderate LUTS. Patients with mild LUTS following TURP had higher The detrusor-pressure during Qmax (PdetQmax), The detrusor-pressure during CCmax (PdetCCmax), preoperative Qmax, Bladder Outlet Obstruction Index (BOOI), Bladder Contractiity Index (BCI) and post-operative Qmax compared to patients who experienced moderate LUTS following TURP (p 0,000; p 0,001; p 0,001; p 0,000; p 0,000 and p 0,000 respectively). Patients with moderate LUTS following TURP had longer in length of urinary retention, had higher The maximum cystometric-capacity (Ccmax), post operative PVR, compared to patients who experienced mild LUTS following TURP (p 0,001; p 0,006 and p 0,000 respectively). No significant differences in age, prostate volume, pre-operative compliance, PVR and weight of resected prostate during TURP between two groups. In almost of all patients with moderate LUTS following TURP had abnormality in bladder contraction (46% with detrusor overactivity and 54% with detrusor underactivity).
Downloads
References
1. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified ? BJU Int. 1999;83:227– 37.
2. Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M, et al. Reoperation , Myocardial Infarction and Mortality after ransurethral and Open Prostatectomy : A Nation-Wide , Long-Term Analysis of 23 , 123 Cases. Eur Urol. 2005;47:499–504.
3. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity , Mortality and Early Outcome of Transurethral Resection of the Prostate : A Prospective Multicenter Evaluation of 10 , 654 Patients. J Urol. 2008;180(July):246–9.
4. Milonas D, Saferis V, Jievaltas M. Transition Zone Index and Bothersomeness of Voiding Symptoms as Predictors of Early Unfavorable Outcomes after Transurethral Resection of Prostate. Urol Int. 2008;81:421–6.
5. Seki N, Takei M, Yamaguchi A, Naito S. Analysis of Prognostic Factors Regarding the Outcome After a Transurethral Resection for Symptomatic Benign Prostatic Enlargement. Neurourol Urodyn. 2006;25(May):428–32.
6. Maderbacher S, Klingler H, Djavan B. Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms ? BJU. 1997;80:72–7.
7. Kevin T Mc Vary. Clinical Evaluation of Benign Prostatic Hyperplasia. Rev Urol. 2003;5:3–11.
8. Abrams P, Cardozo L, Fall M, Gri D, Rosier P, Ulmsten U, et al. The Standardisation of Terminology of Lower Urinary Tract Function : Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.
9. Paul Abrams. Bladder outlet obstruction index , bladder contractility index and bladder voiding e Y ciency : three simple indices to define bladder voiding function. BJU Int. 1999;84:14–5.
10. Homma Y, Kawabe K, Tsukamoto T, Ya H, Okada K, Okajima E, et al. Epidemiologic Survey of lower Urinary Tract Symptoms in Asia and Australia Using the International Prostate Symptom Score. Int JUrol. 1997;4:40– 6.
11. Carson CC, Smith AB. Finasteride in the treatment of patients with benign prostatic hyperplasia : a review. Ther Clin Risk Manag. 2009;5:535–45.
12. Narayan P, Tracchtenberg J, Lepor H, Debruyne EMJ, Tewari A, Stone N, et al. A Dose Response Study of The Effect of Flutamide on BPH : Results of A Multicenter Study. Urology. 1996;47(4):497–504.
13. Joseph MA, Harlow SD, Wei JT, Sarma A V, Dunn RL, Taylor JMG, et al. Risk Factors for Lower Urinary Tract Symptoms in a Population-based Sample of African-American Men. Am J Epidemiol. 2003;157(10):906– 14.
14. Kallenberg F, Hossack TA, Woo HH. Long-Term Followup after Electrocautery Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Adv Urol. 2011;2011:1–6.
15. Roehrborn C. Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice. Eur J Pediatr. 2006;5:698–703.
16. Seki N, Yuki K, Takei M, Yamaguchi A, Naito S. Analysis of the Prognostic Factors for Overactive Bladder Symptoms Following Surgical Treatment in Patients With Benign Prostatic Obstruction. Neurourol Urodyn. 2009;28(April 2008):197–201.
17. Anutrakulchai S. Residual LUTS after Transurethral Resection of Prostate ( TURP ): The Urodynamic Studies in Chiangmai University. Thai J Surg. 2005;26:82–7.
18. Gormley E, Griffiths D, McCracken P, Harrison G, McPhee M. Effect of TURP on detrusor instability urge incontinence in elderly males. Neurourol Urodyn. 1993;12(5):445–53.
19. Kageyama S, Watanabe T, Ushiyama T, Suzuki K, Fujita K. Can persisting detrusor hyperreflexia be predicted after TURP for BPH? Neurourol Urodyn. 2000;19(3):233–40.
20. Kang YJ, Kim KH, Seo Y, Lee KS. Effect of Transurethral Resection of the Prostate on Storage Symptoms in Patients with Benign Prostatic Hyperplasia of Less than 30 ml. World J Mens Health [Internet]. 2013;31(1):64–
9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3640155&tool=pmcentrez&rendertype=abstract
21. Oh C, Choi K, Park R. Relationship between the amount of tissue removed at TURP and clinical improvement in BPH. Korean J Urol. 2003;44(9):866–70.
22. Kristiansen P, Pompeius R, Wadstrom LB. Long term urethral catheter drainage and bladder capacity. Neurourol Urodyn. 1983;2(2):135–43.
23. Souirti, Z., Boujraf, S., Charai, N., Chtaou, N., Belahsen, F., Messouak, O., Messouak, M.Infectious endocarditis complicated by an ischemic stroke and revealing Marfan syndrome(2011) Journal of Cardiovascular Disease Research, 2 (2), pp. 127-129.
DOI: 10.4103/0975-3583.83041
24. Soh, K.G., Raman, R.A., Soh, K.L., Japar, S., Ong, S.L., Ghiami, Z.Parents’ perceptions of their children body fat percentage and weight(2018) International Journal of Pharmaceutical Research, 10 (4), pp. 53-57.
25. Chavda HV, Patel CN, Anand IS. "Biopharmaceutics Classification System." Systematic Reviews in Pharmacy 1.1 (2010), 62-69. Print. doi:10.4103/0975-8453.59514
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
